- Artemether 20 mg/ lumefantrine 120 mg

- Artemether 40 mg/ lumefantrine 240 mg

Weight Dose

- 5 to <15 20 mg/ 120 mg

- 15 to <25 40 mg/ 240 mg

- 25 to <35 60 mg/ 360 mg

- ≥35 80 mg/ 480 mg

Dose administered orally twice daily for 3 days

- Artesunate 25 mg/ mefloquine 55 mg

- Artesunate 100 mg/ mefloquine 220 mg

Weight Dose

- 5 to <9 25 mg/ 55 mg

- 9 to <18 50 mg/ 110 mg

- 18 to <30 100 mg/ 220 mg

- ≥30 200 mg/ 440 mg

Dose administered orally twice daily for 3 days

- Artesunate 25 mg/ amodiaquine 67.5 mg

- Artesunate 50 mg/ amodiaquine 135 mg

- Artesunate 100 mg/ amodiaquine 270 mg

Weight Dose

- 4.5 to <9 25 mg/ 67.5 mg

- 9 to <18 50 mg/ 135 mg

- 18 to <36 100 mg/ 270 mg

- ≥36 200 mg/ 540 mg

Dose administered orally twice daily for 3 days

- Co-packaged scored artesunate tablets (50 mg) and sulfadoxine-pyrimethamine (SP) tablets (500 mg sulfadoxine and 25 mg pyrimethamine)

Weight Artesunate (orally once daily for 3 days) SP (single dose orally on day 1)

- 5 to <10 25 mg 250 mg plus 12.5 mg

- 10 to <25 50 mg 500 mg plus 25 mg

- 25 to <50 100 mg 1000 mg plus 50 mg

- ≥50 200 mg 1500 mg plus 75 mg

- Artesunate 60 mg/ pyronaridine tetraphosphate 180 mg

- For children weighing ≤5 to 20 kg, as an oral suspension of granules from a sachet: Artesunate 20 mg/ pyronaridine tetraphosphate 60 mg

Weight Dose

- ≥5 to <8 20 mg/ 60 mg

- 8 to <15 40 mg/ 120 mg

- 15 to <20 60 mg/ 180 mg (use oral suspension)

- 20 to <24 60 mg/ 180 mg (use tablet)

- 24 to <45 120 mg/ 360 mg

- 45 to <65 180 mg/ 540 mg

- ≥65 240 mg/ 720 mg

Dose administered orally once daily for 3 days

- Dihydroartemisinin 20 mg/ piperaquine 160 mg

- Dihydroartemisinin 40 mg/ piperaquine 320 mg

Weight Dose

- 5 to <8 20 mg/ 160 mg

- 8 to <11 30 mg/ 240 mg

- 11 to <17 40 mg/ 320 mg

- 17 to <25 60 mg/ 480 mg

- 25 to <36 80 mg/ 640 mg

- 36 to <60 120 mg/ 960 mg

- 60 to <80 160 mg/ 1280 mg

- ≥80 200 mg/ 1600 mg

Dose administered orally once daily for 3 days

**Table 1. Artemisinin combination therapy (ACT) regimens for treatment of uncomplicatedPlasmodium falciparum malaria in nonpregnant adults and children**

Quinine: 542 mg base (= 650 mg salt) three times daily for a weekClindamycin: 20 mg base/kg/day (up to 1.8 grams) divided three times daily for a week**OR**Artemisinin combination therapy can be used as an alternate therapy in the first trimester if the above treatment is unavailable or fails.

**Artemether-lumefantrine:**1 tablet = 20 mg artemether and 120 mg lumefantrine. A three-day regimen with a total of six oral doses is recommended as determined by the patient's weight.

- 25 to 34 kg: 3 tablets per dose

- ≥35 kg: 4 tablets per dose)

**Artesunate-amodiaquine:**1 tablet = 100 mg artesunate and 270 mg amodiaquine

- ≥36 kg: 2 tablets per day for three days

**Artesunate-mefloquine:**1 tablet = 100 mg artesunate and 220 mg mefloquine hydrochloride per tablet.

- ≥30 kg: 2 tablets per day for three days

**Dihydroartemisinin-piperaquine:**1 tablet = 40 mg of dihydroartemisinin and 320 mg of piperaquine phosphate.

- 36 to 60 kg: 3 tablets per day for three days

- 60 to 80 kg: 4 tablets per day for three days

**Table 2. Oral regimens for treatment ofPlasmodium falciparum malaria in pregnant women regions with c**hloroquine-resistantP. falciparum infection.****

- 00 hours: 600 mg base (= 1000 mg salt)

- 06 hours: 300 mg base (= 500 mg salt)

- 24 hours: 300 mg base (= 500 mg salt)

- 48 hours: 300 mg base (= 500 mg salt)

- Total dose: 1500 mg base (= 2500 mg salt)

- 00 hours: 620 mg base (= 800 mg salt)

- 06 hours: 310 mg base (= 400 mg salt)

- 24 hours: 310 mg base (= 400 mg salt)

- 48 hours: 310 mg base (= 400 mg salt)

- Total dose: 1550 mg base (= 2000 mg salt)

**Table 3. Oral regimens for treatment ofPlasmodium falciparum malaria in pregnant women in regions with c**hloroquine-sensitiveP. falciparum infection****